Related references
Note: Only part of the references are listed.A Tag-and-Modify Approach to Site-Selective Protein Modification
Justin M. Chalker et al.
ACCOUNTS OF CHEMICAL RESEARCH (2011)
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
A. Palumbo et al.
BRITISH JOURNAL OF CANCER (2011)
Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation
Katharina Frey et al.
INTEGRATIVE BIOLOGY (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Site-Specific and Stoichiometric Conjugation of Cationic Porphyrins to Antiangiogenic Monoclonal Antibodies
Cristina M. A. Alonso et al.
BIOCONJUGATE CHEMISTRY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
Stefanie Sauer et al.
BLOOD (2009)
Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology
Justin M. Chalker et al.
CHEMISTRY-AN ASIAN JOURNAL (2009)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Antibody drug-conjugates targeting the tumor vasculature Current and future developments
Hans-Peter Gerber et al.
MABS (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
Alessandra Villa et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Antibody-based targeting of the tumor vasculature
Christoph Schliemann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2007)
The extra-domain a of fibronectin is a vascular marker of solid tumors and Metastases
Jascha-N. Rybak et al.
CANCER RESEARCH (2007)
Outlook - Development trends for monoclonal antibody cancer therapeutics
Janice M. Reichert et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent
Mark S. Dennis et al.
CANCER RESEARCH (2007)
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F. McDonagh et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate
D Berndorff et al.
CLINICAL CANCER RESEARCH (2005)
Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice
E El-Emir et al.
EUROPEAN JOURNAL OF CANCER (2005)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
L Borsi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
